Genetic Studies Offer Hint Of Clinical Benefits-And Risks- of PCSK9 Inhibitors

–Both cardiovascular benefits and increase in diabetes seem likely. There is no more eagerly awaited question in cardiovascular medicine than the clinical role of the PCSK9 inhibitors. The first reports from a series of outcomes trials are not due until next year. But two large genetic studies published this week deliver strong indirect evidence that...Click here to continue reading...
Source: CardioBrief - Category: Cardiology Authors: Tags: Diabetes Policy & Ethics Prevention, Epidemiology & Outcomes cholesterol genetic variants LDL Mendelian randomization PCSK9 statins Source Type: blogs